Abstract
Purpose: To assess the hepatocyte targeting potential of galactosylated low molecular weight chitosan (Gal-LMWCs)-coated liposomes bearing doxorubicin hydrochloride (DOX).Methods: Chitosan (CS) was depolymerized and lactobionic acid (LA) containing a galactose group was coupled with low molecular weight chitosan (LMWC) using carbodiimide chemistry. Two types of galactosylated polymers with variable degree of substitution were synthesized. Liposomes were prepared using film casting method, coated with the synthesized polymers and characterized for vesicle shape and size, polydispersity, zeta potential, drug entrapment, coating efficiency, in vitro drug release and cytotoxicity on human hepatoma cell line (HepG2).Results: Coating efficiency was greater for the polymer with a lower degree of substitution. The liposomes formed were spherical in shape with a size range of 110 - 160 nm, drug entrapment of 92.14 - 96.37 % and zeta potential of 20.6 - 29.4 mV. Gal-LMWC(s)-coated liposomes exhibited a maximum of 65 % in vitro drug release in 24 h in a sustained fashion. The 50 % inhibitory concentration (IC50) values for liposomal formulations and drug solution were 2.81 and 5.98 μg/ml, respectively.Conclusion: Gal-LMWC (s) coated liposomes containing DOX that demonstrate targetability to human hepatocellular carcinoma cell line (in vitro) have been successfully developed.Keywords: Targeted delivery, Doxorubicin, Galactosylated, Chitosan, Hepatocellular, Carcinoma, Nanoparticles
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.